Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial (TRIM-Line)

NCT05029063 Phase 3 RECRUITING

The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.

Details

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 3
Status	RECRUITING
Enrolment	1828
Start date	2022-10-05
Completion	2027-12

Conditions

• Venous Thromboembolism
• Cancer

Interventions

• Rivaroxaban 10 MG

Primary outcomes

• Major VTE prevention — 90 days (± 3 days) of randomization
  Number of Major VTE's in patient population
• Episodes of Major Bleeding — 90 days (± 3 days) of randomization
  Number of participants who had a major bleed

Countries

Canada